United States · FDA National Drug Code directory
KEYTRUDA QLEX
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0006-3083_18b3adae-863b-413b-8e36-e3551115db37
- Product NDC
- 0006-3083
- Form
- INJECTION, SOLUTION
- Composition / generic term
- pembrolizumab and berahyaluronidase alfa-pmph
- Labeler
- Merck Sharp & Dohme LLC
- Marketing category
- BLA
- Marketing start / end (source format)
- 20250919
- Source listing expiry
- 20271231
Source-listed ingredients
- PEMBROLIZUMAB — 165 mg/mL
- BERAHYALURONIDASE ALFA — 2000 U/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL in 1 CARTON (0006-3083-01) / 2.4 mL in 1 VIAL (0006-3083-99) · 0006-3083-01
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →